News : K101

View:
 

Found press releases

 

MOBERG DERMA SIGNS COMMERCIAL AGREEMENT FOR NAIL FUNGUS PRODUCT K101 WITH LEADIN...

2/27/2009 4:15 AM EST  -   MOBERG DERMA AB
Moberg Derma AB today announces a license and co-promotion agreement with a leading Nordic OTC company for K101 - Moberg Derma’s novel treatment for nail fungus (onychomycosis). In the agreement, Moberg Derma will be responsible for supply of the product and promotion to prescribers, while its Nordic partner will be responsible for promotion to consumers. Financial terms are not disclosed but include up-front and...
Martin Ingman
 

MOBERG DERMA RECRUITS SALES & MARKETING DIRECTOR

12/9/2008 5:30 AM EST  -   MOBERG DERMA AB
The Swedish pharmaceutical company Moberg Derma today announces that it is strengthening its organization through the recruitment of Martin Ingman as Sales & Marketing Director.
Martin Ingman will be responsible for building Moberg Derma’s international network of distributors as well as the company’s sales organisation for the Nordic markets. Martin brings 15 years of experience within sales and marketing. His...
Peter Wolpert, CEO Moberg Derma
 

MOBERG DERMA REPORTS POSITIVE PHASE III RESULTS FOR K101 AGAINST NAIL FUNGUS

11/20/2008 8:50 AM EST  -   MOBERG DERMA AB
Moberg Derma AB reports today positive results from a phase III clinical study for K101 against nail fungus (onychomycosis). In the study, almost 500 patients were treated during six months with K101 or a placebo. The results showed that significantly more patients receiving K101 were cured of their fungal infection (p=0.001). The patients' subjective evaluation of the treatment effect revealed distinct benefits...